LB Investment

Activity from announced rounds

Activity in this selectionOct 22, 2026 · Sep 23, 2026

LB Investment is the Korean investment firm identified as lead by ImpriMed and associated with partner Kiho Park.

Recorded funding activity

ImpriMed tests live cancer cells against medicines and combines the results with clinical data. Point2 develops interconnect hardware, while CarbonSix develops robotic intelligence for manufacturing. These companies retain their distinct products and participant roles.

Sources
Rounds participated in
1
Confirmed lead rounds
1
All roles disclosed
New companies
1
First participation on record · 0 follow-on
Funding in participating rounds
$8.5M
1 disclosed · full round size, not this investor’s share

By stage

Seed1

By primary sector

Climate tech1

By country

United States1

Rounds

1 in this selection
Pascal

Solid-refrigerant cooling systems that combine porous materials and carbon dioxide to move heat.

$8.5MSeed extension
Lead